Detail akcie Lexicon Pharma online

Business Summary: Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Lexicon Pharmaceuticals Inc revenues increased from $139K to $1.2M. Net loss increased 74% to $177.1M. Revenues reflect Net product revenue increase from $0K to $1.1M. Higher net loss reflects Personnel expenses increase from $18.8M to $53M (expense), General and administrative - other increase from $22M to $51.8M (expense), Other Expenses increase from $2.8M to $13.1M (expense).